(HealthDay) -- Afinitor (everolimus) has been approved in combination with the drug exemestane to treat postmenopausal women with advanced hormone-receptor positive, HER2-negative breast cancer, the U.S. Food and Drug Administration ...
Jul 23, 2012
0
0
Federal health regulators on Tuesday approved a highly anticipated medicine from Pfizer Inc. to treat postmenopausal women with a certain type of advanced breast cancer who have not already taken other drugs.
Feb 3, 2015
1
3
(HealthDay)—An experimental cancer drug may delay the progression of some advanced breast cancers, while a double dose of an existing cancer drug could help women live longer, according to separate studies reported Wednesday.
Dec 5, 2012
0
0
Neoadjuvant treatment with the CDK4/6 inhibitor ribociclib (Kisqali) and the aromatase inhibitor letrozole (Femara) produced response rates similar to multi-agent chemotherapy in patients with high-risk luminal B breast cancer, ...
Dec 12, 2019
0
2
The drug palbociclib, an inhibitor of cyclin-dependent kinases (CDK) 4 and 6, significantly improved progression-free survival when administered as a first-line treatment in patients with hormone receptor-positive, metastatic ...
Apr 7, 2014
0
0
Drugmaker Pfizer Inc. said Monday that a midstage study of its experimental drug for advanced breast cancer, palbociclib, met the main goal.
Feb 3, 2014
0
0
Adding the drug dasatinib to a standard antihormone therapy, letrozole, doubled the time before disease progressed for women with hormone receptor-positive, HER2-negative metastatic breast cancer, according to results of ...
Dec 12, 2013
0
0
U.S. regulators have approved a new drug as an initial treatment for postmenopausal women with a type of advanced breast cancer.
Mar 13, 2017
0
0
